CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL and 20 Units per 100 mL of PH Health Limited
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Macitentan tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Rivaroxaban is used to treat venous thromboembolism
Subscribe To Our Newsletter & Stay Updated